GR3002665T3 - Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host - Google Patents

Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host

Info

Publication number
GR3002665T3
GR3002665T3 GR91401273T GR910401273T GR3002665T3 GR 3002665 T3 GR3002665 T3 GR 3002665T3 GR 91401273 T GR91401273 T GR 91401273T GR 910401273 T GR910401273 T GR 910401273T GR 3002665 T3 GR3002665 T3 GR 3002665T3
Authority
GR
Greece
Prior art keywords
drug
incorporation
host
stimulating
capability
Prior art date
Application number
GR91401273T
Other languages
English (en)
Inventor
Eustrate-Stratis Avrameas
Panayota Matsiota-Bernard
Therese Ternynck
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of GR3002665T3 publication Critical patent/GR3002665T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GR91401273T 1987-10-30 1991-09-06 Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host GR3002665T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8715127A FR2622445B1 (fr) 1987-10-30 1987-10-30 Application de groupes nitrophenyles a la stimulation des capacites d'incorporation d'un medicament dans les cellules sensibles de l'hote

Publications (1)

Publication Number Publication Date
GR3002665T3 true GR3002665T3 (en) 1993-01-25

Family

ID=9356379

Family Applications (1)

Application Number Title Priority Date Filing Date
GR91401273T GR3002665T3 (en) 1987-10-30 1991-09-06 Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host

Country Status (9)

Country Link
EP (1) EP0314580B1 (el)
JP (1) JPH02501933A (el)
AT (1) ATE66602T1 (el)
DE (1) DE3864490D1 (el)
DK (1) DK328189D0 (el)
ES (1) ES2037862T3 (el)
FR (1) FR2622445B1 (el)
GR (1) GR3002665T3 (el)
WO (1) WO1989003680A1 (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015200A2 (en) * 1990-04-03 1991-10-17 Radopath Limited Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases

Also Published As

Publication number Publication date
WO1989003680A1 (fr) 1989-05-05
ATE66602T1 (de) 1991-09-15
DE3864490D1 (de) 1991-10-02
ES2037862T3 (es) 1993-07-01
DK328189A (da) 1989-06-30
DK328189D0 (da) 1989-06-30
JPH02501933A (ja) 1990-06-28
EP0314580B1 (fr) 1991-08-28
EP0314580A1 (fr) 1989-05-03
FR2622445A1 (fr) 1989-05-05
FR2622445B1 (fr) 1990-07-27

Similar Documents

Publication Publication Date Title
ATE81986T1 (de) Wirkstoff - monoklonale antikoerper - konjugate.
MX171191B (es) Composiciones farmaceuticas de glipizida
IT8721668A0 (it) Insufflatore per la somministrazione di farmaci sottoforma di polvere predosata in opercoli.
NO883414L (no) Antistoff-enzymkonjugater i kombinasjon med prolegemidlertil fremfoering av cytotoksiske midler til tumorceller.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
BG47033A3 (en) Method for preparing of derivatives of imidazolamine
DK0532525T3 (da) Nye protein-polykationkonjugater
EP0341104A3 (en) Substituted flavonoid compounds, their salts, their manufacture and medicines containing these materials
DE3863678D1 (de) Lithiumsalze enthaltende pharmazeutische zubereitungen.
DK360188A (da) Laegemiddelafgivelsesorgan
MC2289A1 (fr) Composes heterocycliques
IL68456A0 (en) Pharmaceutical compositions comprising perfluorohydrocarbons as vehicles
GR1001017B (el) Δοσολογικη μορφη για την απελευθερωση διαλυτων η αδιαλυτων φαρμακων.
NO883500L (no) Fremgangsmaate for fremstilling av et farmasoeytisk aktivt nitrometan.
FR2417502A1 (fr) Nouvelles 2-phenylimino-imidazolidines substituees, leurs sels d'addition avec des acides, medicaments les renfermant et procedes pour leur preparation
BE856395A (fr) La 2-bromo-6-fluoro-n-2-imidazolinylidene-benzamine, ses sels d'addition avec des acides, procedes pour leur preparation et les medicaments les renfermant.
GR3002665T3 (en) Use of nitrophenyl groups for stimulating the capability of incorporation of a drug into the sensitive cells of a host
SE8705136D0 (sv) Oral doseringsenhet for lekemedel och dess anvendning och framstellning
MY101916A (en) Etoposide oral dosage form.
EP0256385A3 (de) Verwendung von 15-Deoxyspergualin als Arzneimittel
FR2664594B1 (fr) Polymethylene-imines disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant.
IT1223132B (it) Composizione farmaceutica per somministrazione nasale
ATE47664T1 (de) Pharmazeutische dosierungseinheit.
FR2496658B1 (fr) Derives de l'acide nicotinique, leur preparation et medicament contenant ces substances
HU886315D0 (en) Process for the production of pharmaceutical preparations for curing hyperlipaemia, containing oxoquinazoline derivatives as active agents